Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig. 2b
Damuth DL et al. (2024)
|
Xla Wt + Xtr.sox21
NF37/38 (in situ hybridization)
|
|
|
|
Fig. 3 A
Kim Y et al. (2024)
|
Xla Wt + dstn MO
NF16 (in situ hybridization)
|
|
|
|
Fig. 8 AB
Flach H et al. (2024)
|
Xla Wt + CLO (100mg/L)
NF32 (in situ hybridization)
|
|
|
|
Sup. Fig. 3 CD
Flach H et al. (2024)
|
Xla Wt + CLO (100mg/L)
NF32 (in situ hybridization)
|
|
|
|
Fig 8 AB
Flach H et al. (2024)
|
Xla Wt + Imidacloprid (100mg/l)
NF32 (in situ hybridization)
|
|
|
|
Fig. 8 AB
Flach H et al. (2024)
|
Xla wt + TMX (100mg/L)
NF32 (in situ hybridization)
|
|
|
|
Fig. 2 A
Ismail T et al. (2024)
|
Xla Wt +PFOS
NF35/36 (in situ hybridization)
|
|
|
|
Fig. 3 B
Yamamoto T et al. (2023)
|
Xla Wt + hs6st1 CRISPR
NF15 (in situ hybridization)
|
|
|
|
Fig. 2 B r1, C; B r2, C
Yamamoto T et al. (2023)
|
Xla Wt + hs6st1.L
NF15 (in situ hybridization)
|
|
|
|
Fig. 8. A. B
Pandey A et al. (2023)
|
Xla Wt + adam11 + animal cap explant + dissociation
NF20 (western blot)
|
|
|